Bristol Myers deepens ADC pipeline in $1B+ biobuck pact with Munich startup

Kyle LaHucik

Senior Reporter

Most of the antibody-drug conjugate talk lately has been centered around Pfizer’s $43 billion deal with Seagen, but Bristol Myers Squibb is looking to up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers deepens ADC pipeline in $1B+ biobuck pact with Munich startup

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Bris­tol My­ers deep­ens ADC pipeline in $1B+ biobuck pact with Mu­nich start­up

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Bristol Myers deepens ADC pipeline in $1B+ biobuck pact with Munich startup